CVS Stock Overview
Provides health solutions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
CVS Health Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$44.36 |
| 52 Week High | US$83.25 |
| 52 Week Low | US$43.60 |
| Beta | 0.54 |
| 1 Month Change | -21.94% |
| 3 Month Change | -22.87% |
| 1 Year Change | -43.68% |
| 3 Year Change | -56.21% |
| 5 Year Change | -40.38% |
| Change since IPO | 6,656.82% |
Recent News & Updates
Recent updates
CVS Health: When The Industry Is In Crisis, Don't Pick The Weaker Players
Dec 10There May Be Some Bright Spots In CVS Health's (NYSE:CVS) Earnings
Nov 19
CVS Health: Cheap But No Signs Of Turnaround (Yet)
Nov 06CVS Health (NYSE:CVS) Has A Somewhat Strained Balance Sheet
Nov 03CVS Health Stock Dip: Undervalued And Ready For A Turnaround
Oct 24CVS Health: Glenview's Activism Ramps Up Pressure On Management
Sep 30CVS Health: At Least There's A Valuable Lesson (Rating Downgrade)
Sep 10A Piece Of The Puzzle Missing From CVS Health Corporation's (NYSE:CVS) Share Price
Aug 08CVS Health Q2 Earnings: CEO's Swinging Axe May Have Ended The Bear Run
Aug 07Here's Why CVS Health (NYSE:CVS) Has A Meaningful Debt Burden
Jul 21CVS Health: A Better Investment Than Walgreens Boots Alliance
Jul 09Vltava Fund - CVS Health Corp.: Why We Sold CVS
Jul 03CVS Health: Mismanagement, Eroding Moat And Poor Momentum Make It A Sell
Jun 21The Correct Play On CVS Health
Jun 06CVS Health: Downside Movement Is Overdramatic
May 26CVS Health: Secure Dividend And Upside Potential Presents Compelling Opportunity
May 15We Think Shareholders Are Less Likely To Approve A Pay Rise For CVS Health Corporation's (NYSE:CVS) CEO For Now
May 10CVS Health: A Terrible Earnings Report, But An Undervalued Stock
May 04CVS Health Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
May 03CVS Health: 8x P/E, 8% Growth Projection - It's A Market Blind Spot
Apr 22Sentiment Still Eluding CVS Health Corporation (NYSE:CVS)
Apr 14CVS Health: Lookback, Management Guidance Vs. Results 2018-To-Date
Apr 10Does CVS Health (NYSE:CVS) Have A Healthy Balance Sheet?
Mar 27CVS Health: Better Times Likely Ahead
Mar 12CVS Health: Lower Guidance But Risk/Reward Remains Attractive
Feb 15Shareholder Returns
| CVS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -10.1% | -4.1% | -2.4% |
| 1Y | -43.7% | -10.2% | 23.3% |
Return vs Industry: CVS underperformed the US Healthcare industry which returned -10.2% over the past year.
Return vs Market: CVS underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| CVS volatility | |
|---|---|
| CVS Average Weekly Movement | 6.6% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CVS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CVS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 259,500 | J. Joyner | www.cvshealth.com |
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
CVS Health Corporation Fundamentals Summary
| CVS fundamental statistics | |
|---|---|
| Market cap | US$55.09b |
| Earnings (TTM) | US$5.02b |
| Revenue (TTM) | US$367.25b |
11.1x
P/E Ratio0.2x
P/S RatioIs CVS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CVS income statement (TTM) | |
|---|---|
| Revenue | US$367.25b |
| Cost of Revenue | US$316.53b |
| Gross Profit | US$50.71b |
| Other Expenses | US$45.70b |
| Earnings | US$5.02b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 12, 2025
| Earnings per share (EPS) | 3.99 |
| Gross Margin | 13.81% |
| Net Profit Margin | 1.37% |
| Debt/Equity Ratio | 85.4% |
How did CVS perform over the long term?
See historical performance and comparisonDividends
6.0%
Current Dividend Yield66%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 22:31 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CVS Health Corporation is covered by 63 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Harshit Gupta | Accountability Research Corporation |
| Christopher Graja | Argus Research Company |
| Samuel Hudson | Atlantic Equities LLP |